Arumakimig clinical trials
Also written MAS825.
How each study uses arumakimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the arumakimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Novartis Pharmaceuticals (7) · The Hospital for Sick Children (1)
Often tested with
Tested in the same studies.
Iscalimab (1) · LYS-006 (1) · Remibrutinib (1) · Ianalumab (1) · NLRP3 Inhibitor DFV890 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test arumakimig.
- Apr 2027A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseasePhase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses arumakimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruitingPhase 2Novartis PharmaceuticalsNCT07203001Written as MAS825
- A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodRecruitingPhase 2Novartis PharmaceuticalsNCT07748624Written as Arumakimig
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798Written as MAS825
- Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04641442Written as MAS825
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)CompletedPhase 2Novartis PharmaceuticalsNCT06097663Written as MAS825
- A Single-patient Clinical Trial of MAS825 in a Patient With XIAP DeficiencyCompletedPhase 3The Hospital for Sick ChildrenNCT06309823Written as MAS825
- A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy VolunteersCompletedPhase 1Novartis PharmaceuticalsNCT04665154Written as MAS825
- Study of Efficacy and Safety of MAS825 in Patients With COVID-19CompletedPhase 2Novartis PharmaceuticalsNCT04382651Written as MAS825
Codes
What other systems call arumakimig · ClinicalTrials.gg INT016604
- UNII (FDA) FWE2G0Y2W3ARUMAKIMIGOne source FDA
- NCI Thesaurus C215726ArumakimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FWE2G0Y2W3 | ARUMAKIMIG | One source FDA |
| NCI Thesaurus | C215726 | Arumakimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.